{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-08-27",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 6
    }
  },
  "results": [
    {
      "discontinued_date": "11/03/2025",
      "update_type": "New",
      "initial_posting_date": "11/03/2025",
      "package_ndc": "0002-4312-62",
      "generic_name": "Lasmiditan Succinate Tablet",
      "contact_info": "800-545-5979",
      "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.",
      "openfda": {
        "application_number": [
          "NDA211280"
        ],
        "brand_name": [
          "REYVOW"
        ],
        "generic_name": [
          "LASMIDITAN"
        ],
        "manufacturer_name": [
          "Eli Lilly and Company"
        ],
        "product_ndc": [
          "0002-4312",
          "0002-4491"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "LASMIDITAN"
        ],
        "rxcui": [
          "2256937",
          "2256943",
          "2256945",
          "2256947"
        ],
        "spl_id": [
          "29f467c6-0365-4831-b4ce-9a0eefaf5896"
        ],
        "spl_set_id": [
          "aea3358c-ff41-4490-9e6d-c7bf7b3de13f"
        ],
        "package_ndc": [
          "0002-4312-08",
          "0002-4312-61",
          "0002-4312-62",
          "0002-4491-08",
          "0002-4491-61",
          "0002-4491-62"
        ],
        "unii": [
          "760I9WM792"
        ]
      },
      "update_date": "11/03/2025",
      "therapeutic_category": [
        "Neurology"
      ],
      "dosage_form": "Tablet",
      "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-62)",
      "company_name": "Eli Lilly and Co.",
      "status": "To Be Discontinued"
    }
  ]
}